# A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

> **NCT07568236** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 54 (estimated)

## Conditions studied

- Vasomotor Symptoms
- Prostate Cancer

## Interventions

- **DRUG:** Fezolinetant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07568236
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07568236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07568236, "A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07568236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*